VP, Bioanalytical Development
- Expertise
- Services
- Solutions
- About Us
- Resources
Expertise
Services
Solutions
About Us
Resources
Meticulous In-Vitro DMPK Studies To Characterize And Understand Your Drug Profile!
- DMPK Assay For Metabolic Stability In Liver Microsomes And Other Applicable Biological Fractions
- Cytochrome P450 Inhibition, Induction, And Polymorphism DMPK Studies To Evaluate Drug Safety And Food Or Drug Interaction
- Caco-2, MDCK-1, Or Pampa DMPK Assays To Determine Gut, BBB, Or Cellular Permeability
- Plasma Protein Binding DMPK To Assess Free Drug Level In The Body
Regulated And Inspected By:
Provide Your Bioanalysis Study Details
We Will Respond Within 1 Business Day
Click below for answers to your DMPK Development questions -
Ask Us About Your Study
Expert Drug Metabolism and Pharmacokinetics (DMPK) services to identify the metabolic pathways, drug interactions, and ADME routes of your compound at an early stage
What is Drug Metabolism and Pharmacokinetics (DMPK)?
Drug Metabolism and Pharmacokinetics (DMPK): Understanding Dosage, Toxicity, and Therapeutic Index
Drug metabolism and pharmacokinetics, or commonly referred to as DMPK, is a scientific discipline within drug discovery, dealing with safety and efficacy evaluation of drug candidates before entering clinical trials. DMPK studies come along with absorption, distribution, metabolism, excretion, and toxicity analysis (ADMET) of drug candidates. The DMPK discipline is the basis for optimizing compounds so that bioavailability, drug-drug interactions (DDI), and related risks to a drug compound can be evaluated. Assessment of DMPK profiles minimizes the rate of attrition of drug candidates and increases the efficiency of drug discovery overall.
The objective of DMPK studies is to evaluate multiple properties of drugs, such as clearance, distribution volume, half-life, bioavailability, drug-drug interaction, and metabolic profile. Evaluation of CYP, other drug enzymes, transporters, and inhibition and induction minimize the rate of potential DDI liabilities and reduce attrition for lack of efficacy and poor safety profiles. Another benefit of DMPK studies during drug discovery and development is that it allows chemists and analysts to achieve reasonable structural modifications such that pharmacokinetic properties and efficacy of the drug can be improved.
Sponsors Love Our Bioanalytical Laboratory Services For Top Quality And Industry Leading Turnaround
Connect With Us For A Reference Call With Them!
NorthEast BioLab is a responsive, collaborative, and reliable partner
We trust NorthEast BioLab to design and execute streamlined, impactful bioanalytical projects
We found their integrity as refreshing as readiness to provide creative scientific input and high-quality data
We have worked with NorthEast BioLab for over ten years given their commitment to highest quality bioanalytical data.
NorthEast BioLab tremendously supported us in reproducing our critical lab discoveries for drug metabolism
NorthEast BioLab always exceeds expectations on bioanalytical assay development, validation, and sample analysis.
“NorthEast BioLab goes the extra mile. We look forward to more meaningful collaborations.”
NorthEast BioLab offers a science-based, hands-on approach to the latest bioanalytical platforms
We are thrilled to complete our bioanalytical studies with their top quality and incredibly responsive team.
We worked closely to implement the most efficient and cost-effective bioanalytical assay for our PK Studies.
Our projects with NorthEast BioLab include successful method development, validation, stability studies during Clinical Phase I – IV studies.
NorthEast BioLab provides critical insight, and are compliant with regulatory standards and industry best practices. We highly recommend them and look forward to working together again.
Our latest successful study was a pivotal bioequivalence study, where samples from a cross-over study with about 100 volunteers needed swift analysis.
This study, same as all other bioanalytical studies, was completed with top quality and reporting standard with incredible responsiveness.
NorthEast BioLab’s scientists deliver high-quality data on time and within budget
Tackle Your Drug Metabolism And Pharmacokinetics With Our Veteran Team Now!
Which DMPK studies does NorthEast BioLab offer?
DMPK Services by NorthEast BioLab
DMPK studies are carried out throughout the drug discovery, preclinical development, and clinical trials. Furthermore, DMPK studies in animals are essential for drug development as the obtained data informs about the compound behavior in the human body. Popular DMPK Assays offered by NorthEast BioLab, include:
In-vitro ADME Studies
- Kinetic solubility, thermodynamic solubility, chemical stability, and logD
- Stability studies in plasma, buffer, serum and simulated gastric/intestinal fluid, brain/tissue homogenate binding
- Phase1/2 metabolic stability, including hepatocytes
- Metabolite profiling
- Permeability Assays (PAMPA, CACO2, MDCK-MDR1)
- Cytochrome P450 inhibition, TDI (Time Dependent inhibition), CYP phenotyping
- Cytochrome P450 (CYP) induction studies
- CYP2B6 and CYP1A2 induction studies
- Blood Plasma Partitioning in multiple species
- Plasma Protein Binding (PPB) assays across all species such as rats, mice, humans, pigs, dogs, and monkeys
Ex-vivo ADME Studies
- Discrete and cassette Pharmacokinetics (PK) studies
- Brain to plasma ratio (B/P)
- Tissue distribution studies
- Single and multiples dosing in rodents
- Dose range finding
- Bioequivalence and Bioavailability Studies
- Serial sampling following IV, PO, SC administration in rats and mice
- Evaluation and reporting of PK parameters such as Tmax, Cmax, t1/2, AUC (0-inf), AUC(0-last), Vd, CL, MRT by Phoenix WinNonlin software
- Compartmental & noncompartmental analysis (NCA)
- Metabolite identification studies by LC-MS/MS for both in vitro and in vivo samples
Other DMPK studies
- DMPK pharmacokinetics in rabbit, monkey, and dog species in the preclinical phase
- Method development, validation, and bioanalysis of human clinical samples by LC-MS/MS in the clinical phase
Registered And Inspected By Various Regulatory Agencies
Don’t Wait, Start Your Drug Metabolism And Pharmacokinetics Service Today!
Why Choose us for your DMPK Assay Setup and Sample Analysis Studies?
Excellent DMPK Services to beat Competitors to the Market
DMPK studies are crucial to efficacy and safety assessment of your drug compounds throughout the discovery, preclinical, and clinical development phases. NorthEast BioLab utilizes its leading DMPK assay expertise and precise method development practices to ensure an excellent outcome for your drug candidates. Our scientists even collaborate with your other vendors to evaluate and aid in the development of study designs, protocols, analytical methods, and calculation of pharmacokinetic parameters. Afterward, we happily assist with reviewing and interpreting the results from these DMPK studies. We perform bioanalysis and drug metabolism studies and can coordinate in-vitro ADME and in-vivo pharmacokinetics results to aid your program in the assessment of efficacious and toxicological exposures, therapeutic indices, and drug-drug interaction potential. Our team provides you high-quality preclinical findings to help with the dose selection and cost of goods estimation for early clinical trials. Furthermore, we help establish bioanalytical methods for assessment of clinical PK as your product progresses clinical trials, leading towards efficient and effective market release of your drug product.
The Basics of Bioanalysis
Bioanalysis is an essential tool in drug discovery and development for determining the concentration of drugs and their metabolites as well as various pharmacodynamics biomarkers in biological fluids. In these analyses, scientists use developed an….
What is the significance of various DMPK Assays?
DMPK Assays: Plasma Protein Binding, Microsomal Stability, CYP450 Inhibition, etc
DMPK studies offer an understanding of the dose regimen, toxicity level, therapeutic index, PK/PD relationships, and other PK parameters. DMPK studies during drug discovery and development utilize two to four animal doses for testing the generic formulation of a compound.
Typically, the oral dose level is 10mg/kg, and the intravenous dose level is 1mg/kg. Either single Compound Dosing (Discrete Dosing), or high-throughput Cassette Dosing (N–in–one) method can be implemented to obtain the pharmacokinetic data. For both dosing regimens, the blood samples are collected at specified time points and analyzed by techniques such as LC-MS/MS or ELISA Assay.
Here’s a list of several industry-standard DMPK assays performed during IND-enabling studies:
In Vitro Toxicity Assay
The in vitro toxicity assays are developed to asses toxic mechanisms corresponding to a drug compound. These mechanisms may include metabolite induction, reactivity, cytotoxicity, and mutagenicity. These DMPK studies allow evaluating the toxic effects of drug candidates ahead of the animal studies. In vitro toxicity assays include:
- Mutagenicity/Genotoxicity
- hERG block assay
- Ames assay
- Cytotoxicity
- Glutathione trapping assay
Blood Plasma Partitioning Assay
DMPK pharmacokinetics obtained from plasma can be misleading, owing to the preferential drug binding to Red Blood Cells. The blood to plasma ratio presents relevant and informative data about drug distribution in blood and provides investigators a better understanding of the drug pharmacokinetic behavior in animal or clinical ADME studies.
Plasma Protein Binding Assay
This type of assay provides information about the unbound fraction of drug in plasma. Usually, it is performed using an equilibrium dialysis method. Upon reaching the equilibrium between the compound spiked plasma sample and buffer system, a value of the fraction of a compound unbound to proteins (fu) can be calculated.
In Vitro Microsomal Stability Assay
During in vitro microsomal stability assay, the test sample dissolved in DMSO is incubated with microsomal fraction in the presence of a co-factor at 37°C. The aliquots are then removed at a particular time and analyzed by techniques, such as LC-MS/MS MS and ELISA Assay. Upon drug depletion over time, clearance rate can be estimated.
CYP Inhibition Assay
CYP enzymes are primary targets in the assessment of drug-drug interactions leading to potentially toxic effects. For general DMPK assay, the CYP isozyme isoform or combination, industry accepted substrate compound, and the test compound at several concentrations are incubated together. The difference in the formation of metabolite for each given substrate/CYP enzyme can be calculated along with IC50 value.
CYP Induction Assay
The induction of CYP increases the drug metabolizing enzyme’s activity through activation of nuclear receptors leading to induction of their gene expression. This results in a reduction of the therapeutic concentration of the drug compound, which may become the cause of reduced drug efficacy or increased risk of toxicity.
The mechanism of CYP induction is assessed with nuclear receptors:
- Aryl Hydrocarbon Receptor (AhR)
- Constitutive Androstane Receptor (CAR)
- Pregnane X Receptor (PXR)
